CD274 and non-small cell lung carcinoma: Six patients who received treatment on a clinical trial of epigenetic therapy for advanced treatment-refractory NSCLC were placed on trials for immunotherapy targeting the PD-1/PD-L1 immune tolerance checkpoint.